Skip to main content

Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

The contractor, Palmetto GBA, has expanded its coverage policy for all qualified Medicare patients to include those with ductal carcinoma in situ, or DCIS, Genomic Health said. The coverage policy took effect May 8.

The Redwood City, Calif.-based company said that detection of DCIS is increasing in the US with more than 50,000 patients diagnosed each year. The Oncotype DX DCIS Score predicts 10-year local recurrence, DCIS or invasive carcinoma, based on the patient's underlying tumor biology, Genomic Health said.

The company last week reported that revenues in the first quarter increased 8 percent year over year driven by adoption of its Onctotype DX products.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.